Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TAK) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · TAK · as of Sep 30, 2025
Ownership Breakdown
338
Institutional Holders
▲ 21 vs Q2
$1.25B
Total Inst. Value
▲ $45.52M vs Q2
3.16B
Shares Outstanding
freeFloat 100.00%
85.27M
13F Shares Held
▲ 7.46M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
TAK largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
CAPITAL RESEARCH GLOBAL INVESTORS pharmaceutical preparations | 13.40M | 42.83% | 42.83% | $196.24B | Nov 13, 2025 | ▲ 108.6K |
MORGAN STANLEY pharmaceutical preparations | 7.69M | 24.57% | 24.57% | $112.59B | May 27, 2026 | ▲ 70.8K |
UBS GROUP AG pharmaceutical preparations | 5.89M | 18.83% | 18.83% | $86.29B | Nov 13, 2025 | ▲ 1.87M |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 4.95M | 15.83% | 15.83% | $72.52B | Nov 14, 2025 | ▲ 452.4K |
FMR LLC pharmaceutical preparations | 4.19M | 13.38% | 13.38% | $61.30B | Nov 13, 2025 | ▲ 85.3K |
BRANDES INVESTMENT PARTNERS, LP pharmaceutical preparations | 3.93M | 12.56% | 12.56% | $57.56B | Nov 14, 2025 | ▲ 219.5K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 3.86M | 12.35% | 12.35% | $56.58B | Nov 13, 2025 | ▲ 565.4K |
BLACKROCK, INC. pharmaceutical preparations | 3.31M | 10.57% | 10.57% | $48.42B | Nov 12, 2025 | ▼ 243.3K |
TORONTO DOMINION BANK pharmaceutical preparations | 3.00M | 9.60% | 9.60% | $43.98B | Nov 14, 2025 | ▲ 3.00M |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP pharmaceutical preparations | 2.83M | 9.04% | 9.04% | $41.41B | Nov 13, 2025 | ▲ 1.61M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
36
Increased
+12.86M shares0
New Positions
first time holders14
Decreased
−2.27M shares0
Sold Out
fully exitedNet shares change (top 50)
+10.59M
+12.86M / −2.27M
Net new holders
+22
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
TAK insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Weber Christophe Pierre President and CEO | Apr 27, 2026 | Award | 78,900 | — | — | 1.01M | Form 4 ↗ |
Weber Christophe Pierre President and CEO | Apr 27, 2026 | Award | 165,370 | — | — | 418.8K | Form 4 ↗ |
Weber Christophe Pierre President and CEO | Apr 27, 2026 | Award | 78,978 | — | — | 125.3K | Form 4 ↗ |
Furuta Milano Chief Financial Officer | Apr 27, 2026 | Award | 7,800 | — | — | 57.9K | Form 4 ↗ |
Furuta Milano Chief Financial Officer | Apr 27, 2026 | Award | 7,814 | — | — | 16.6K | Form 4 ↗ |
Plump Andrew Stewart President, R&D | Apr 27, 2026 | Award | 212,470 | — | — | 806.6K | Form 4 ↗ |
Ricci Gabriele Chief Data & Tech. Officer | Apr 27, 2026 | Award | 34,994 | — | — | 159.1K | Form 4 ↗ |
Bitetti Teresa Marie President, OBU | Apr 27, 2026 | Award | 64,988 | — | — | 258.1K | Form 4 ↗ |
Duprey Lauren Rusckowski Chief Transformation Officer | Apr 27, 2026 | Award | 59,990 | — | — | 228.5K | Form 4 ↗ |
Kim Julie So-Young CEO - Elect | Apr 27, 2026 | Award | 105,416 | — | — | 430.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Takeda Pharmaceutical Company Limited (TAK) is primarily owned by institutional investors, who hold approximately 2.7% of total shares outstanding. Company insiders own approximately 0.00%, while retail and public investors account for the remaining 97.30%.
The largest institutional shareholder of Takeda Pharmaceutical Company Limited is CAPITAL RESEARCH GLOBAL INVESTORS, holding approximately 13.40 million shares — equal to 42.83% of outstanding shares — as of September 30, 2025.
A total of 338 institutional investors currently hold TAK stock, with a combined institutional value of approximately $1.25 billion as of the most recent 13F filing period.
Frequently asked questions
TAK ownershipTakeda Pharmaceutical Company Limited (TAK) is primarily owned by institutional investors, who hold approximately 2.7% of shares. The largest shareholder is CAPITAL RESEARCH GLOBAL INVESTORS with a 42.83% stake. Company insiders hold 0.00%. Data sourced from SEC Form 13F as of September 30, 2025.